Alzamend Neuro (ALZN) Non-Current Deffered Revenue (2024)
Alzamend Neuro's (ALZN) quarterly Non-Current Deffered Revenue came in at $742263.0 in Q1 2024.
Powered by 
Analysis
Alzamend Neuro (ALZN) Non-Current Deffered Revenue (2024) Analysis & Trends
Alzamend Neuro has disclosed Non-Current Deffered Revenue across 1 years of filings, most recently posting $742263.0 for Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.31 Bn | 193.32 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.04 Bn | 175.86 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 131.34 Bn | 123.48 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.84 Bn | 73.85 Bn | 3.93 Bn | 220.40 Mn |
| 5 | Argenx Se | 61.21 Bn | 56.03 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.12 Bn | 47.98 Bn | 52.00 Mn | 147.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.32 Bn | 30.02 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.66 Bn | 30.38 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.36 Bn | 29.36 Bn | 1.16 Mn | - |
| 10 | Alzamend Neuro | 5.57 Mn | 5.57 Mn | - | - |